ORIENT BIO Inc. (KRX:002630)
South Korea flag South Korea · Delayed Price · Currency is KRW
623.00
+16.00 (2.64%)
At close: Sep 8, 2025

ORIENT BIO Revenue

ORIENT BIO had revenue of 17.21B KRW in the quarter ending December 31, 2021, with 21.77% growth. This brings the company's revenue in the last twelve months to 59.09B, up 19.53% year-over-year. In the fiscal year ending March 31, 2021, ORIENT BIO had annual revenue of 52.02B with 39.79% growth.

Revenue (ttm)
59.09B
Revenue Growth
+19.53%
P/S Ratio
1.25
Revenue / Employee
472.73M
Employees
125
Market Cap
73.87B

Revenue Chart

Revenue History

Fiscal Year EndRevenueChangeGrowth
Mar 31, 202152.02B14.81B39.79%
Mar 31, 202037.21B6.84B22.52%
Mar 31, 201930.37B4.75B18.53%
Mar 31, 201825.62B-83.39B-76.50%
Mar 31, 2017109.02B3.97B3.78%
Mar 31, 2016 Pro Pro Pro
Mar 31, 2015 Pro Pro Pro
Mar 31, 2014 Pro Pro Pro
Mar 31, 2013 Pro Pro Pro
Mar 31, 2012 Pro Pro Pro

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company NameRevenue
Samsung Biologics5,031.69B
Celltrion3,748.95B
ALTEOGEN158.06B
Yuhan2,165.44B
SK Biopharmaceuticals620.28B
Peptron5.18B
PharmaResearch449.81B
ABL Bio94.93B
Revenue Rankings